Literature DB >> 11133739

The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis.

E Haddad1, J L Zugaza, F Louache, N Debili, C Crouin, K Schwarz, A Fischer, W Vainchenker, J Bertoglio.   

Abstract

In studies aimed at further characterizing the cellular immunodeficiency of the Wiskott-Aldrich syndrome (WAS), we found that T lymphocytes from WAS patients display abnormal chemotaxis in response to the T-cell chemoattractant stromal cell-derived factor (SDF)-1. The Wiskott- Aldrich syndrome protein (WASP), together with the Rho family GTPase Cdc42, control stimulus-induced actin cytoskeleton rearrangements that are involved in cell motility. Because WASP is an effector of Cdc42, we further studied how Cdc42 and WASP are involved in SDF-1-induced chemotaxis of T lymphocytes. We provide here direct evidence that SDF-1 activates Cdc42. We then specifically investigated the role of the interaction between Cdc42 and WASP in SDF-1-responsive cells. This was achieved by abrogating this interaction with a recombinant polypeptide (TAT-CRIB), comprising the Cdc42/Rac interactive binding (CRIB) domain of WASP and a human immunodeficiency virus-TAT peptide that renders the fusion protein cell-permeant. This TAT-CRIB protein was shown to bind specifically to Cdc42-GTP and to inhibit the chemotactic response of a T-cell line to SDF-1. Altogether, these data demonstrate that Cdc42-WASP interaction is critical for SDF-1-induced chemotaxis of T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133739     DOI: 10.1182/blood.v97.1.33

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

Review 1.  Regulation of hematopoiesis by chemokine family members.

Authors:  H E Broxmeyer
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

2.  An MEK-cofilin signalling module controls migration of human T cells in 3D but not 2D environments.

Authors:  Martin Klemke; Elisabeth Kramer; Mathias H Konstandin; Guido H Wabnitz; Yvonne Samstag
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

3.  Protein transduction as a means of effective manipulation of Cdc42 activity in primary T cells.

Authors:  Irina Tskvitaria-Fuller; Neeta Mistry; Shining Sun; Christoph Wülfing
Journal:  J Immunol Methods       Date:  2006-12-08       Impact factor: 2.303

4.  The N-terminus of Dictyostelium Scar interacts with Abi and HSPC300 and is essential for proper regulation and function.

Authors:  Diana Caracino; Cheryl Jones; Mark Compton; Charles L Saxe
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

5.  Syk regulates multiple signaling pathways leading to CX3CL1 chemotaxis in macrophages.

Authors:  Haein Park; Dianne Cox
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

Review 6.  RHO GTPases: from new partners to complex immune syndromes.

Authors:  Rana El Masri; Jérôme Delon
Journal:  Nat Rev Immunol       Date:  2021-02-05       Impact factor: 53.106

7.  Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor.

Authors:  Sabine Charrier; Michael Blundell; Gregory Cédrone; Fawzia Louache; William Vainchenker; Adrian J Thrasher; Anne Galy
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

8.  An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages.

Authors:  Ricky Cheung; Mobeen Malik; Vipa Ravyn; Brian Tomkowicz; Andrzej Ptasznik; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2009-07-20       Impact factor: 4.962

Review 9.  Chemokine coreceptor signaling in HIV-1 infection and pathogenesis.

Authors:  Yuntao Wu; Alyson Yoder
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

Review 10.  The WASP and WAVE family proteins.

Authors:  Shusaku Kurisu; Tadaomi Takenawa
Journal:  Genome Biol       Date:  2009-06-15       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.